In this issue:
– Guideline for the management of hypertrophic cardiomyopathy
– Performance and quality measures for valvular and structural heart disease
– Expert Consensus Statement on cardiac amyloidosis
– Effect of SGLT2 inhibitors on heart failure outcomes
– Semaglutide reduces the need for loop diuretics in heart failure
– Vaccination against COVID-19 and clinical outcomes in heart failure
– SEQUOIA-HCM trial in obstructive hypertrophic cardiomyopathy
– Nurse Practitioner prescribing for empagliflozin amended
– Lokelma approved for hyperkalaemia
– Artificial intelligence and its role in diagnosing heart failure
– Yoga linked to improved heart failure symptoms
– Robot-assisted PCI
Download Australian Heart Failure Practice Review: Issue 5, with commentary by Prof Andrew Coats.

